Analysts’ Weekly Ratings Changes for NeoGenomics (NEO)

Several analysts have recently updated their ratings and price targets for NeoGenomics (NASDAQ: NEO):

• 7/29/2026 – NeoGenomics had its “buy” rating reaffirmed by Craig Hallum. They now have a $19.00 price target on the stock.
• 7/29/2026 – NeoGenomics had its price target raised by Needham & Company LLC from $15.00 to $19.00. They now have a “buy” rating on the stock.
• 7/24/2026 – NeoGenomics had its price target raised by Benchmark Co. from $11.00 to $16.00. They now have a “buy” rating on the stock.
• 7/15/2026 – NeoGenomics had its “buy” rating reaffirmed by TD Cowen.
• 7/14/2026 – NeoGenomics was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 6/29/2026 – NeoGenomics was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 6/27/2026 – NeoGenomics was upgraded by Wall Street Zen from “hold” to “buy”.
• 6/8/2026 – NeoGenomics was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.

Insider Buying and Selling at NeoGenomics

In other NeoGenomics news, Director Lynn A. Tetrault sold 5,307 shares of the firm’s stock in a transaction on Tuesday, June 9th. The stock was sold at an average price of $11.29, for a total transaction of $59,916.03. Following the completion of the transaction, the director owned 91,422 shares of the company’s stock, valued at approximately $1,032,154.38. This trade represents a 5.49% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 1.10% of the stock is currently owned by corporate insiders.

NeoGenomics, traded on the Nasdaq under the symbol NEO, is a leading provider of cancer-focused genetic and molecular testing services. Headquartered in Fort Myers, Florida, the company operates an integrated network of CAP-accredited and CLIA-certified laboratories across the United States, Europe and Asia. NeoGenomics delivers diagnostic insights that support oncologists, pathologists and healthcare institutions in the detection, prognosis and treatment of hematologic and solid tumor cancers.

The company’s core service offerings include flow cytometry, immunohistochemistry, fluorescence in situ hybridization (FISH), karyotyping and advanced molecular assays such as next-generation sequencing (NGS) panels and polymerase chain reaction (PCR) tests.